Hoth Therapeutics, Inc. (HOTH)
Hoth Therapeutics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Hoboken, NY, US. The stock last traded at $0.80, down 2.22% on the session, giving a market capitalisation of $10.6M. On trailing twelve-month figures it carries a trailing P/E of -0.99, a net margin of 0.0%. Its beta of 0.53 implies it has historically moved less than the broad market.
Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. Its product pipeline focuses on potential treatments for indications including atopic dermatitis (also known as eczema), chronic wounds, psoriasis, asthma, and acne. It offers the BioLexa Platform, a drug compound platform for the treatment of eczema. The company was founded by Robbie Knie, Matthew D. Eitner, and James Ahern on May 16, 2017 and is headquartered in New York, NY.
Hoth Therapeutics, Inc. is most often compared with the following Healthcare names: